Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.60 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912586 | 1.00 | CASP1 (0.60) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL7583002 | 1.00 | CASP1 (0.60) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL7975561 | 0.92 | CASP1 (0.55) | CASP1PPARAPPARGCTSKCTSL | |
| SCHEMBL3012469 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL755795 | 0.91 | MMP9 (0.52) | CASP1PPARAPPARGCTSKCTSL | |
| SCHEMBL8116799 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL3012475 | 0.91 | CASP1 (0.56) | CASP1PPARAPPARGCTSKTACR1 | |
| SCHEMBL9312398 | 0.91 | CASP1 (0.60) | CASP1CTSKTACR1CTRB1CTSL | |
| SCHEMBL8765627 | 0.91 | CASP1 (0.60) | CASP1CTSKTACR1CTRB1CTSL | |
| SCHEMBL376886 | 0.89 | CASP1 (0.67) | CASP1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049064-A9 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20240270765-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116075499-A | Novel dephosphorylated galectin derivatives with prodrug properties | 指南针探路者有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-8962551-B2 | Quinoxalinyl derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2222161-A1 | QUINOXALINYL DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009073719-A1 | QUINOXALINYL DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| EP-0604186-B1 | Inhibitors of HIV protease useful for the treatment of aids | LILLY CO ELI (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5491166-A | ENZYME INHIBITORS, VIRICIDES | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180981-A1 | QUINOXALINYL DERIVATIVES | SQOR, ATG4A, NQO1 | CASP1 246/4885PPARA 3035/4885PPARG 3682/4885 |
| US-20240025928-A1 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | CASP1 1666/4885PPARA 568/4885PPARG 819/4885 |
| US-20240270765-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | CPT1B, FABP3, NR1H2 | CASP1 1666/4885PPARA 568/4885PPARG 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.